Recommended changes to oncology clinical trial design: revolution or evolution?
about
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designDose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expressionExposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.Do single-arm trials have a role in drug development plans incorporating randomised trials?Randomized phase II designs.Issues in using progression-free survival when evaluating oncology productsComparison of power between randomized discontinuation design and upfront randomization design on progression-free survival.Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?Determinants of the recommended phase 2 dose of molecular targeted agents.On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review.
P2860
Q26830525-ECC073AF-E65C-4E63-9E12-5A0B7CDEA06AQ30665810-694E509F-DAB5-484B-ADE0-36728B3FC124Q30968729-98055A65-197A-431F-A780-46710E1BB89EQ34587714-2DB6FA8C-4BEE-4BF9-AD5B-849127F4A334Q35677873-CD854815-B774-44D1-9403-5DBDD706A17AQ35914787-940F6DE4-943F-4884-93BA-39CB40E683CBQ36866317-88111340-270C-40BB-8A65-836ACE5AD983Q37173942-368DBF65-335D-4740-9EC6-78E590448B23Q37231532-29F0629D-30B1-4D50-856D-38AD6AA7E9D1Q37325089-374A15B8-D740-4AEF-BA9D-C8BD9FC9231EQ37671970-415332FE-06D7-47A2-BFC0-62A778D0CC91Q39128248-6DA50AE1-0383-462B-99CC-C67CBD956EBBQ45993673-686E0F0E-4D8F-4CD6-A048-AB7843E47295Q47163554-0846EA64-540B-42E5-B042-D33124A963D4
P2860
Recommended changes to oncology clinical trial design: revolution or evolution?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Recommended changes to oncology clinical trial design: revolution or evolution?
@en
Recommended changes to oncology clinical trial design: revolution or evolution?
@nl
type
label
Recommended changes to oncology clinical trial design: revolution or evolution?
@en
Recommended changes to oncology clinical trial design: revolution or evolution?
@nl
prefLabel
Recommended changes to oncology clinical trial design: revolution or evolution?
@en
Recommended changes to oncology clinical trial design: revolution or evolution?
@nl
P2093
P2860
P1476
Recommended changes to oncology clinical trial design: revolution or evolution?
@en
P2093
Carl C Peck
Donald A Berry
Gary B Gordon
Peter C Adamson
Rachel W Humphrey
Thomas R Fleming
Walter M Stadler
P2860
P356
10.1016/J.EJCA.2007.09.011
P577
2007-11-05T00:00:00Z